TY - JOUR
T1 - A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease
AU - Verwey, N. A.
AU - Van Der Flier, W. M.
AU - Blennow, K.
AU - Clark, C.
AU - Sokolow, S.
AU - De Deyn, P. P.
AU - Galasko, D.
AU - Hampel, H.
AU - Hartmann, T.
AU - Kapaki, E.
AU - Lannfelt, L.
AU - Mehta, P. D.
AU - Parnetti, L.
AU - Petzold, A.
AU - Pirttila, T.
AU - Saleh, L.
AU - Skinningsrud, A.
AU - V Swieten, J. C.
AU - Verbeek, M. M.
AU - Wiltfang, J.
AU - Younkin, S.
AU - Scheltens, P.
AU - Blankenstein, M. A.
PY - 2009/5
Y1 - 2009/5
N2 - Background: Different cerebrospinal fluid (CSF) amyloid-beta 1-42 (Aβ 1-42), total Tau (Tau) and Tau phosphorylated at threonine 181 (P-Tau) levels are reported, but currently there is a lack of quality control programmes. The aim of this study was to compare the measurements of these CSF biomarkers, between and within centres. Methods: Three CSF-pool sampleswere distributed to 13 laboratories in 2004 and thesame sampleswere again distributed to 18 laboratories in 2008. In 2004 six laboratories measured Aβ 1-42, Tau and P-Tau and seven laboratories measured one or two of these marker(s) by enzyme-linked immunosorbent assays (ELISAs). In 2008, 12 laboratories measured all three markers, three laboratories measured one or two marker(s) by ELISAs and three laboratories measured the markers by Luminex. Results: In 2004, the ELISA intercentre coefficients of variance (interCV) were 31%, 21% and 13% for Aβ 1-42, Tau and P-Tau, respectively. These were 37%, 16% and 15%, respectively, in 2008. When we restricted the analysis to the Innotestw (N = 13) for Aβ 1-42, lower interCV were calculated (22%). The centres that participated in both years (N = 9) showed interCVs of 21%, 15% and 9% and intra-centre coefficients (intraCV) of variance of 25%,18% and 7% in 2008. Conclusions: The highest variability was found for Aβ 1-42. The variabilities for Tau and P-Tau were lower in both years. The centres that participated in both years showed a high intraCV comparable to their interCV, indicating that there is not only a high variation between but also within centres. Besides a uniform standardization of (pre)analytical procedures, the same assay should be used to decrease the inter/intracentre variation.
AB - Background: Different cerebrospinal fluid (CSF) amyloid-beta 1-42 (Aβ 1-42), total Tau (Tau) and Tau phosphorylated at threonine 181 (P-Tau) levels are reported, but currently there is a lack of quality control programmes. The aim of this study was to compare the measurements of these CSF biomarkers, between and within centres. Methods: Three CSF-pool sampleswere distributed to 13 laboratories in 2004 and thesame sampleswere again distributed to 18 laboratories in 2008. In 2004 six laboratories measured Aβ 1-42, Tau and P-Tau and seven laboratories measured one or two of these marker(s) by enzyme-linked immunosorbent assays (ELISAs). In 2008, 12 laboratories measured all three markers, three laboratories measured one or two marker(s) by ELISAs and three laboratories measured the markers by Luminex. Results: In 2004, the ELISA intercentre coefficients of variance (interCV) were 31%, 21% and 13% for Aβ 1-42, Tau and P-Tau, respectively. These were 37%, 16% and 15%, respectively, in 2008. When we restricted the analysis to the Innotestw (N = 13) for Aβ 1-42, lower interCV were calculated (22%). The centres that participated in both years (N = 9) showed interCVs of 21%, 15% and 9% and intra-centre coefficients (intraCV) of variance of 25%,18% and 7% in 2008. Conclusions: The highest variability was found for Aβ 1-42. The variabilities for Tau and P-Tau were lower in both years. The centres that participated in both years showed a high intraCV comparable to their interCV, indicating that there is not only a high variation between but also within centres. Besides a uniform standardization of (pre)analytical procedures, the same assay should be used to decrease the inter/intracentre variation.
UR - http://www.scopus.com/inward/record.url?scp=66249127876&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=66249127876&partnerID=8YFLogxK
U2 - 10.1258/acb.2009.008232
DO - 10.1258/acb.2009.008232
M3 - Article
C2 - 19342441
AN - SCOPUS:66249127876
SN - 0004-5632
VL - 46
SP - 235
EP - 240
JO - Annals of Clinical Biochemistry
JF - Annals of Clinical Biochemistry
IS - 3
ER -